Detailed explanation of the contraindications of estramustine (Adelax) and which patients should avoid its use

Estramustine (Estramustine) is an anti-tumor drug that combines the structure of estrogen and nitrogen mustard. It is mainly used for the adjuvant treatment of prostate cancer and the control of advanced cases. Its pharmacological properties determine that estramustine has certain selectivity and limitations in clinical application, but it also brings a series of potential safety risks. Therefore, before using estramustine, fully understanding its contraindications and which patients should avoid its use is of great significance to ensure patient safety and improve treatment compliance.

First, one of the main contraindications to estramustine is in patients who are allergic to this drug or other estrogen-based drugs. Allergic reactions may manifest as rash, itching, difficulty breathing or even anaphylactic shock. Such reactions may occur when the drug is first used or may accumulate during long-term use. Therefore, the use of estramustine should be strictly avoided in patients with a history of allergy to estrogen drugs. Clinically, doctors usually ask about allergy history in detail before prescribing drugs, and if necessary, conduct allergy tests or choose alternative treatment options to reduce the risk of serious adverse reactions.

Second, estramustine is not suitable for patients at risk for thromboembolism. Estramustine has certain estrogenic activity and may increase blood coagulation tendency, thereby inducing deep vein thrombosis, pulmonary embolism or cerebrovascular events. In particular, patients with a history of thrombosis, long-term bed rest, obesity, smoking, or combined use of other procoagulant drugs are at a significantly increased risk of thrombotic events after taking estramustine. Therefore, such patients need to assess the risk of thrombosis before treatment, and if necessary, conduct hematological tests or use anticoagulant prophylaxis, but in most cases it is recommended to avoid it completely to reduce the risk of life.

Third, estramustine should be used with caution or avoided in patients with hepatic impairment or liver disease. Estramustine is mainly metabolized by the liver, and its drugs and metabolites may accumulate when liver function is damaged, increasing the risk of drug toxicity and side effects, such as further deterioration of liver function or the occurrence of drug-induced hepatitis. For patients with severe liver damage, estramustine may increase the burden on the liver, leading to jaundice, abnormal coagulation function, and liver failure. Therefore, in patients with abnormal liver function or previous liver disease, the risks of use should be carefully assessed, other treatment options should be selected if necessary, and liver function indicators should be strictly monitored during medication.

In addition, patients with cardiovascular disease also need to be cautious. Estramustine may cause sodium and water retention, increased blood pressure, and abnormal heart rhythms, so patients with a history of severe hypertension, heart failure, myocardial infarction, or arrhythmias are at higher risk when using it. Long-term estrogen exposure may also increase the incidence of cardiovascular events. Therefore, such patients should have their cardiac function evaluated before taking the drug, and if necessary, adjust the dose or choose alternative therapies under the guidance of the cardiology department, and closely monitor blood pressure, heart rate, and cardiac imaging indicators during treatment.

Pregnant and lactating women are also contraindicated with estramustine. Estramustine has strong estrogenic activity and cytotoxicity and may cause serious effects on the fetus or infant, including malformations or abnormal growth and development. Although most prostate cancer patients are male, attention should be paid to a small number of studies on female breast cancer or other indications. Pregnant women should avoid contact with or use estramustine, and lactating women should suspend breastfeeding or choose other treatment options to prevent the drug from causing toxic effects on the baby through milk.

Finally, estramustine should also be used with caution in patients with preexisting bleeding disorders, severe renal impairment, or active ulcers. Estramustine may cause thrombocytopenia, coagulation abnormalities, or accumulation of nephrotoxicity, which may have adverse effects on the underlying diseases of these patients, thereby increasing the risk of bleeding or renal damage. Clinically, if use is indeed necessary, the dose should be carefully adjusted under hematology, renal function and gastrointestinal function monitoring, and the risk-benefit ratio should be strictly evaluated.

In summary, contraindications for the use of estramustine include: those who are allergic to estrogen, those at risk of thromboembolism, patients with liver insufficiency, patients with cardiovascular disease, pregnant and lactating women, and patients with severe bleeding or renal impairment. In clinical applications, doctors should scientifically assess the risks of medication based on the patient's specific medical history, laboratory tests and concomitant medication, and adopt alternative plans or strict monitoring when necessary to ensure that patients obtain the maximum therapeutic effect while minimizing potential safety risks. This is not only a prerequisite for ensuring the safety of treatment, but also the key to improving patients' quality of life and compliance with efficacy.

Reference materials:https://www.drugs.com/